Table 3: Susceptibility to antibiotics of the most frequent bacterias isolated.

Antibiotic

Escherichia coli

Klebsiella pneumoniae

Enterococcus faecalis

Pseudomonas aeruginosa

Sensitive

Resistant

Sensitive

Resistant

Sensitive

Resistant

Sensitive

Resistant

Ampicillin

32.2%

67.8%

-

100%

100%

-

-

-

Amoxicillin and clavulanic acid

58.33%

41.67%

60%

40%

-

-

-

-

Ticarcillin

32.79%

67.21%

-

100%

-

-

100%

 

Ticarcillin and clavulanic acid

61.67%

38.33%

62.5%

37.5%

-

-

87.5%

12.5%

Piperacillin

32.76 %

67.24%

-

100%

-

-

85.71%

14.29%

Piperacillin and Tazobactam

82.26%

17.74%

68.75%

31.25%

-

-

100%

-

Mecillinam

84.75%

15.25%

92.86%

7.14%

-

-

-

-

Cefalexin

61.67%

38.33%

81.25%

18.75%

-

-

-

-

Cefoxitin

94.59%

5.41%

80%

20%

-

-

-

-

Cefuroxime

75.41%

24.59%

81.25%

18.75%

-

-

-

-

Cefixime

76.27%

23.73%

81.25%

18.75%

-

-

-

-

Cefotaxime

75%

25%

81.25%

18.75%

-

-

-

-

Ceftazidime

75.41%

24.59%

81.25%

18.75%

-

-

87.5%

12.5%

Cefepime

80%

20%

81.25%

18.75%

-

-

87.5%

12.5%

Aztreonam

80.36%

19.64%

81.25%

18.75%

-

-

100%

-

Ertapenem

100%

-

87.5%

12.5%

-

-

-

-

Imipenem

100%

-

84.62%

15.38%

-

-

87.5%

12.5%

Meropenem

100%

-

87.5%

12.5%

-

-

-

-

Gentamicin

85.45%

14.55%

66.67%

33.33%

-

-

100%

-

Tobramycin

79.31%

20.69%

71.43%

28.57%

-

-

100%

-

Amikacin

95%

5%

92.86%

7.14%

-

-

100%

-

Netilmicin

87.1%

12.9%

68.75%

31.25%

-

-

-

-

Tigecycline

100%

-

-

-

-

-

-

-

Nalidixic Acid

51.67%

48.33%

62.50%

37.5%

-

-

-

-

Norfloxacin

63.64%

36.36%

71.43%

28.57%

-

-

-

-

Ciprofloxacin

60.66%

39.34%

66.67%

33.33%

-

-

87.5%

12.5%

Trimethoprim

55.74%

44.26%

53.8%

46.2%

-

-

-

-

Trimethoprim- Sulfamethoxazole

57.14%

42.86%

53.8%

46.2%

-

-

-

-

Fosfomycin

97.83%

2.17%

100%

-

-

-

-

-

Furans

100%

-

71.43%

28.57%

-

-

-

-

Colistin

-

-

10%

90%

-

-

-

-

Glycopeptide

-

-

-

-

100%

-

-

-